Clinical Trials / Scientific
Evidence
Every Fikzol™ Collagen bottle is backed by human clinical trials
and scientific evidence supporting both safety and efficacy in each
Fikzol™ Collagen capsule, tablet, powder and serving size.
Because the Natural Product Industry is now fully regulated, and as
required by the regulatory process, all our human clinical trials and
scientific evidence have been submitted, reviewed and accepted by
Health Canada which further supports and represents all our NPN’s
featured on all our labels.
The NPN (Natural Product Number) we proudly feature on each of
our Fikzol™ labels classifies and confirms that all our products contain
medicinal collagen as the active ingredient and proudly offer effective
therapeutic strength for effective therapeutic use.
We encourage you to visit our link titled Medicinal vs Non-Medicinal.
Hydrolyzed Collagen Clinical
Study
During the annual congress of the "European League Against
Rheumatism" (EULAR) in Berlin (9th to 12th June 2004), a new
clinical US study was presented showing a signifigant improvement
in knee function in patients with osteoarthritis of the knee after
taking hydrolyzed collagen. An in-vitro study that was also
presented shows a significant stimulation of cartilage metabolism.
These latest results confirm findings that have been made through
clinical and experimental observation in recent years.
For almost 25 years the effect of hydrolyzed collagen in the treatment
of degenerative joint disease has been investigated. Clinical studies
carried out so far clearly demonstrate the positive influence of hydro-
lyzed collagen in reducing pain and improving joint mobility in
patients with osteoarthritis. Dr. James Rippe, Massachusetts, USA,
in 2004 presented to the EULAR Congress the latest results from
a clinical study which shows improved joint mobility after taking
hydrolyzed collagen.
The randomised, double-blind study (Rippe et. al. submitted for
publication) investigated knee pain, stiffness, joint mobility,
flexibility and development of strength in 190 patients with mild
osteoarthritis of the knee. Over a period of 14 weeks those affected
were given a daily dose of 10 grams of hydrolyzed collagen (plus 300
milligrams of calcium plus 60 milligrams of vitamin C) or placebo.
By using isometric and isokinetic measurements, changes of the
parameters, mentioned above, were determined in the patients. The
results showed a significant improvement in physical joint function.
The patients that received hydrolyzed collagen developed more
strength in the region of the joint than prior to treatment. These data
illustrate that the ingestion of hydrolyzed collagen can distinctly improve
the functionality of the knee in case of osteoarthritis.
Dr. Steffen Oesser, Collagen Research Institute, Kiel, presented to the
EULAR Congress a further important building block in the research
referring to the mechanism of action of hydrolyzed collagen. In an
in-vitro experiment Oesser was able to show a significant, dose-related
stimulation of type II collagen synthesis in chondrocytes when hydro-
lyzed collagen was added. After the addition of hydrolyzed
collagen there was also a significant increase in pericellular
proteoglycans. In contrast no increase in protease activity was
observed. "These results indicate an increase in synthesis activity
in the whole extracellular matrix of the cartilage. Therefore, hydro-
lyzed collagen has become increasingly important, as far as nu-
trition for individuals with degenerative disease of cartilage
tissue is concerned“, explained Oesser. The new data again confirm
the results of a publication dealing with "bovine" cells which
appeared in the study (Oesser et al. 2003). As early as 1999 a
research group led by Oesser produced evidence of intestinal
absorption of hydrolyzed collagen at an average peptide size
of 3.5 kDa. After absorption collagen fragments accumulated
significantly and exclusively in the joint cartilage.